https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-rally-hits-a-wall-this-other-drugmaker-stole-the-showContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-rally-hits-a-wall-this-other-drugmaker-stole-the-showhttps://www.live-feeds.com/feed/moderna-s-cancer-vaccine-rally-hits-a-wall-this-other-drugmaker-stole-the-show#u163292Fri, 30 Oct 2026 08:51:56 +0000Moderna shares experienced significant volatility following an early data leak from the Phase 3 INTerpath-001 trial evaluating its personalized mRNA cancer vaccine, intismeran autogene, alongside Merck's Keytruda for melanoma. Although the trial successfully met its goal by reducing the risk of cancer recurrence or death by 42 percent compared to Keytruda alone, initial investor disappointment triggered a stock selloff and an 18 percent drop for Moderna. Meanwhile, other pharmaceutical competitors such as Amgen captured market enthusiasm by showcasing strong data for alternative oncology